🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Advanced Unresectable or Metastatic Breast Cancer

A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy NCT07071337Phase 32 sites📍 Beijing📍 Guangzhou Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Tests: SKB264, Nab-paclitaxel, Paclitaxel, Capecitabine A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) NCT07648914Phase 31 site📍 Beijing Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1, Albumin-Bound Paclitaxel, Paclitaxel, Capecitabine Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer NCT06434064Phase 21 site📍 Buffalo Roswell Park Cancer Institute · Tests: Biopsy, Biospecimen Collection, Computed Tomography, Echocardiography, Magnetic Resonance Imaging A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC NCT07002177Phase 1, Phase 21 site📍 Shanghai Forward Pharmaceuticals Co., Ltd. · Tests: FWD1802, Palbociclib 125mg, Ribociclib 200Mg Oral Tablet, Abemaciclib 150 MG, Everolimus 10 mg A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors NCT07488676Phase 1, Phase 221 sites📍 Birmingham📍 Los Angeles📍 Miami Astellas Pharma Global Development, Inc. · Tests: ASP546C Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. NCT06590857Phase 1, Phase 231 sites📍 Phoenix📍 Irvine📍 San Diego RayzeBio, Inc. · Tests: RYZ101, Standard of Care Endocrine Therapy A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors NCT06827613Phase 1, Phase 28 sites📍 Los Angeles📍 Los Angeles📍 Boston Marengo Therapeutics, Inc. · Tests: STAR0602, Sacituzumab Govitecan (SG) Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer NCT05111561Phase 14 sites📍 Boston📍 Boston📍 Galveston National Cancer Institute (NCI) · Tests: BET Bromodomain Inhibitor ZEN-3694, Binimetinib, Biopsy Procedure, Biospecimen Collection, Computed Tomography A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) NCT06312176Phase 3259 sites📍 Chandler📍 Gilbert📍 Fullerton Merck Sharp & Dohme LLC · Tests: Sacituzumab tirumotecan, Pembrolizumab, Paclitaxel, Nab-paclitaxel, Capecitabine YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer NCT07461454Phase 31 site📍 Shanghai MediLink Therapeutics (Suzhou) Co., Ltd. · Tests: YL202, Eribulin, Capecitabine, Gemcitabine, Vinorelbine A Study of NX-1607 in Adults With Advanced Malignancies NCT05107674Phase 117 sites📍 Duarte📍 Los Angeles📍 San Francisco Nurix Therapeutics, Inc. · Tests: NX-1607, Paclitaxel A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer NCT07389733Phase 1, Phase 22 sites📍 Dalian📍 Chengdu Shandong Suncadia Medicine Co., Ltd. · Tests: HRS-6208 Capsule, HRS-6209 Capsule, HRS-8080 Tablet, Fulvestrant injection, Letrozole tablets A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid Tumors NCT06555068Phase 1, Phase 21 site📍 Shanghai Jiangsu HengRui Medicine Co., Ltd. · Tests: HRS-6209 in Combination with Fulvestrant, HRS-6209 in Combination with HRS-1358, HRS-6209 in Combination with Letrozole… A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC. NCT06064812Phase 1, Phase 222 sites📍 Hefei📍 Guangzhou📍 Huizhou Forward Pharmaceuticals Co., Ltd. · Tests: FWD1802 A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors NCT06493864Phase 11 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B16D1 Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer NCT05098210Phase 11 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC, Echocardiography Test, Multigated Acquisition Scan RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive NCT07413939Phase 2, Phase 3206 sites📍 Huntsville📍 Gilbert📍 San Francisco Hoffmann-La Roche · Tests: RO7771950, Tucatinib, Trastuzumab, Capecitabine A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer NCT06471205Phase 21 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1, PD-1 Monoclonal Antibody Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer NCT06642545Phase 21 site📍 Beijing RemeGen Co., Ltd. · Tests: Disitamab Vedotin, RC148, Albumin-bound Paclitaxone, Toripalimab A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors NCT05706129Phase 1, Phase 210 sites📍 Melbourne📍 Sydney📍 Clermont-Ferrand Lumara Bio Oncologics GmbH · Tests: [68Ga]Ga-DPI-4452, [177Lu]Lu-DPI-4452 A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) NCT06760819Phase 254 sites📍 Birmingham📍 Duarte📍 Fort Myers Bayer · Tests: BAY2927088 Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer NCT04965766Phase 211 sites📍 Dijon📍 Limoges📍 Lyon Gustave Roussy, Cancer Campus, Grand Paris · Tests: U3-1402 Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer NCT06331169Phase 11 site📍 Shanghai Fudan University · Tests: Anlotinib, Trastuzumab deruxtecan Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer NCT06081959Phase 31 site📍 Beijing Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Tests: SKB264, Eribulin, Capecitabine, Gemcitabine, Vinorelbine A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer NCT07597629Phase 21 site📍 Harbin CSPC Megalith Biopharmaceutical Co.,Ltd. · Tests: SYS6023, KN026 ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer NCT06224673Phase 21 site📍 San Francisco Laura Huppert, MD, BA · Tests: ARX788, Computed Tomography (CT), Biospecimen Collection, Amiloride Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer NCT06993506n/a19 sites📍 Hefei📍 Beijing📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: SKB264 Monotherapy or Combination Therapy A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC) NCT02819882n/a40 sites📍 Elche📍 Manresa📍 Terrassa Spanish Breast Cancer Research Group · Tests: No intervention A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression NCT06682793Phase 1, Phase 210 sites📍 Gilbert📍 La Jolla📍 Los Angeles A2 Biotherapeutics Inc. · Tests: A2B395, xT CDx with HLA-LOH assay A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients NCT06679036Phase 1, Phase 22 sites📍 Harbin📍 Zhengzhou Shandong Suncadia Medicine Co., Ltd. · Tests: HRS-2189, Fluvustat, HRS-8080, HRS-6209, HRS-1358
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy